Pages that link to "Q35798966"

The following pages link to Axitinib increases the infiltration of immune cells and reduces the suppressive capacity of monocytic MDSCs in an intracranial mouse melanoma model. (Q35798966):

Displaying 24 items.

• Combined VEGFR and CTLA-4 blockade increases the antigen-presenting function of intratumoral DCs and reduces the suppressive capacity of intratumoral MDSCs (Q37447879) (← links)
• Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustion. (Q38776701) (← links)
• Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma (Q38870929) (← links)
• Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma (Q38955815) (← links)
• Targeted Therapy and Immunosuppression in the Tumor Microenvironment (Q39441315) (← links)
• The FDA approved PI3K inhibitor GDC-0941 enhances in vitro the anti-neoplastic efficacy of Axitinib against c-myc-amplified high-risk medulloblastoma. (Q48150834) (← links)
• Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma. (Q48228251) (← links)
• Maintaining unperturbed cerebral blood flow is key in the study of brain metastasis and its interactions with stress and inflammatory responses. (Q48300160) (← links)
• Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma. (Q48865058) (← links)
• Combinatorial effects of VEGFR kinase inhibitor axitinib and oncolytic virotherapy in mouse and human glioblastoma stem-like cell models. (Q52337612) (← links)
• The role of tumor microenvironment in resistance to anti-angiogenic therapy. (Q52645823) (← links)
• Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review. (Q52682465) (← links)
• Targeting VEGF/VEGFR to Modulate Antitumor Immunity. (Q55008337) (← links)
• Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy (Q57817490) (← links)
• Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression (Q58780996) (← links)
• Turning "Cold" Into "Hot" Tumors-Opportunities and Challenges for Radio-Immunotherapy Against Primary and Metastatic Brain Cancers (Q64075498) (← links)
• Innovative Therapeutic Strategies for Effective Treatment of Brain Metastases (Q64093580) (← links)
• Myeloid Derived Suppressor Cells Interactions With Natural Killer Cells and Pro-angiogenic Activities: Roles in Tumor Progression (Q64102304) (← links)
• Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma (Q89169504) (← links)
• Oncolytic Virus Encoding a Master Pro-Inflammatory Cytokine Interleukin 12 in Cancer Immunotherapy (Q89682703) (← links)
• The role of the immune system in brain metastasis (Q92092437) (← links)
• Targeting Myeloid Cells in Combination Treatments for Glioma and Other Tumors (Q92511358) (← links)
• Modulation of Immunosuppression by Oligonucleotide-Based Molecules and Small Molecules Targeting Myeloid-Derived Suppressor Cells (Q92731408) (← links)
• The Endless Saga of Monocyte Diversity (Q92857692) (← links)